The SOX9 upstream region prone to chromosomal aberrations causing campomelic dysplasia contains multiple cartilage enhancers

Two decades after the discovery that heterozygous mutations within and around SOX9 cause campomelic dysplasia, a generalized skeleton malformation syndrome, it is well established that SOX9 is a master transcription factor in chondrocytes. In contrast, the mechanisms whereby translocations in the –350/–50-kb region 5′ of SOX9 cause severe disease and whereby SOX9 expression is specified in chondrocytes remain scarcely known. We here screen this upstream region and uncover multiple enhancers that activate Sox9-promoter transgenes in the SOX9 expression domain. Three of them are primarily active in chondrocytes. E250 (located at –250 kb) confines its activity to condensed prechondrocytes, E195 mainly targets proliferating chondrocytes, and E84 is potent in all differentiated chondrocytes. E84 and E195 synergize with E70, previously shown to be active in most Sox9-expressing somatic tissues, including cartilage. While SOX9 protein powerfully activates E70, it does not control E250. It requires its SOX5/SOX6 chondrogenic partners to robustly activate E195 and additional factors to activate E84. Altogether, these results indicate that SOX9 expression in chondrocytes relies on widely spread transcriptional modules whose synergistic and overlapping activities are driven by SOX9, SOX5/SOX6 and other factors. They help elucidate mechanisms underlying campomelic dysplasia and will likely help uncover other disease mechanisms.

[1]  Y. Mishina,et al.  BMP-Smad4 signaling is required for precartilaginous mesenchymal condensation independent of Sox9 in the mouse. , 2015, Developmental biology.

[2]  H. Akiyama,et al.  Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes. , 2015, Human molecular genetics.

[3]  A. Lassar,et al.  A pathway to bone: signaling molecules and transcription factors involved in chondrocyte development and maturation , 2015, Development.

[4]  V. Lefebvre,et al.  SOXC proteins amplify canonical WNT signaling to secure nonchondrocytic fates in skeletogenesis , 2014, The Journal of cell biology.

[5]  K. Lyons,et al.  TGFβ signaling in cartilage development and maintenance. , 2014, Birth defects research. Part C, Embryo today : reviews.

[6]  P. Koopman,et al.  Building the mammalian testis: origins, differentiation, and assembly of the component cell populations , 2013, Genes & development.

[7]  R. Young,et al.  Super-Enhancers in the Control of Cell Identity and Disease , 2013, Cell.

[8]  Y. Kawaguchi Sox9 and programming of liver and pancreatic progenitors. , 2013, The Journal of clinical investigation.

[9]  David A. Orlando,et al.  Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes , 2013, Cell.

[10]  V. Lefebvre,et al.  A far-upstream (−70 kb) enhancer mediates Sox9 auto-regulation in somatic tissues during development and adult regeneration , 2013, Nucleic acids research.

[11]  B. de Crombrugghe,et al.  The postnatal role of Sox9 in cartilage , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  S. Wray,et al.  Neural Crest and Olfactory System: New Prospective , 2012, Molecular Neurobiology.

[13]  V. Lefebvre,et al.  Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. , 2012, Developmental cell.

[14]  Manuel Serrano,et al.  Oncogenicity of the developmental transcription factor Sox9. , 2012, Cancer research.

[15]  V. Lefebvre,et al.  Unraveling the transcriptional regulatory machinery in chondrogenesis , 2011, Journal of Bone and Mineral Metabolism.

[16]  M. Wegner,et al.  SOX9 controls epithelial branching by activating RET effector genes during kidney development. , 2011, Human molecular genetics.

[17]  M. Wegner,et al.  SoxE function in vertebrate nervous system development. , 2010, The international journal of biochemistry & cell biology.

[18]  Véronique Lefebvre,et al.  The SoxD transcription factors--Sox5, Sox6, and Sox13--are key cell fate modulators. , 2010, The international journal of biochemistry & cell biology.

[19]  D. Fitzpatrick,et al.  Long-range regulation at the SOX9 locus in development and disease , 2009, Journal of Medical Genetics.

[20]  A. Lassar,et al.  The Transcriptional Activity of Sox9 in Chondrocytes Is Regulated by RhoA Signaling and Actin Polymerization , 2009, Molecular and Cellular Biology.

[21]  A. Munnich,et al.  Highly conserved non-coding elements on either side of SOX9 associated with Pierre Robin sequence , 2009, Nature Genetics.

[22]  V. Lefebvre,et al.  L-Sox5 and Sox6 Drive Expression of the Aggrecan Gene in Cartilage by Securing Binding of Sox9 to a Far-Upstream Enhancer , 2008, Molecular and Cellular Biology.

[23]  R. Lovell-Badge,et al.  Sex determination involves synergistic action of SRY and SF1 on a specific Sox9 enhancer , 2008, Nature.

[24]  T. Aigner,et al.  SOX Gene Expression in Human Osteoarthritic Cartilage , 2008, Pathobiology.

[25]  P. Stankiewicz,et al.  Two novel translocation breakpoints upstream of SOX9 define borders of the proximal and distal breakpoint cluster region in campomelic dysplasia , 2006, Clinical genetics.

[26]  K. Tezuka,et al.  [Notch signaling in chondrogenesis]. , 2006, Clinical calcium.

[27]  U. Dohrmann,et al.  Long-range upstream and downstream enhancers control distinct subsets of the complex spatiotemporal Sox9 expression pattern. , 2006, Developmental biology.

[28]  J. Deng,et al.  Osteo-chondroprogenitor cells are derived from Sox9 expressing precursors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Stankiewicz,et al.  Position effects due to chromosome breakpoints that map ∼900 Kb upstream and ∼1.3 Mb downstream of SOX9 in two patients with campomelic dysplasia , 2005 .

[30]  T. Yamashiro,et al.  Possible Roles of Runx1 and Sox9 in Incipient Intramembranous Ossification , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  J. Epstein,et al.  Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Kimura,et al.  The establishment and characterization of an immortal cell line with a stable chondrocytic phenotype , 2003, Journal of cellular biochemistry.

[33]  Marie-Christine Chaboissier,et al.  The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. , 2002, Genes & development.

[34]  V. Lefebvre,et al.  The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. , 2001, Developmental cell.

[35]  J. Deng,et al.  Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Birren,et al.  Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region. , 1999, American journal of human genetics.

[37]  Richard R. Behringer,et al.  Sox9 is required for cartilage formation , 1999, Nature Genetics.

[38]  Véronique Lefebvre,et al.  A new long form of Sox5 (L‐Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene , 1998, The EMBO journal.

[39]  P N Goodfellow,et al.  Deletion of long-range regulatory elements upstream of SOX9 causes campomelic dysplasia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  V. Lefebvre,et al.  Use of a New Rat Chondrosarcoma Cell line to Delineate a 119-Base Pair Chondrocyte-specific Enhancer Element and to Define Active Promoter Segments in the Mouse Pro-α1(II) Collagen Gene (*) , 1995, The Journal of Biological Chemistry.

[41]  N. Tommerup,et al.  Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9 , 1994, Cell.

[42]  Sahar Mansour,et al.  Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene , 1994, Nature.

[43]  Peter A. Jones,et al.  Multiple new phenotypes induced in 10T 1 2 and 3T3 cells treated with 5-azacytidine , 1979, Cell.

[44]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[45]  H. Mefford,et al.  Campomelic Dysplasia -- GeneReviews(®) , 2016 .

[46]  M. Wegner,et al.  From CNS stem cells to neurons and glia: Sox for everyone , 2014, Cell and Tissue Research.

[47]  V. Jain,et al.  Campomelic dysplasia. , 2014, Journal of pediatric orthopedics. Part B.

[48]  T. Ochi,et al.  Regional differences in chondrocyte metabolism in osteoarthritis: a detailed analysis by laser capture microdissection. , 2008, Arthritis and rheumatism.

[49]  P. Stankiewicz,et al.  Position effects due to chromosome breakpoints that map approximately 900 Kb upstream and approximately 1.3 Mb downstream of SOX9 in two patients with campomelic dysplasia. , 2005, American journal of human genetics.

[50]  O. Haas,et al.  Mutational analysis of the SOX9 gene in campomelic dysplasia and autosomal sex reversal: lack of genotype/phenotype correlations. , 1997, Human molecular genetics.